VentriPoint Diagnostics Ltd (TSE:VPT)
:VPT
Top Page
VentriPoint Diagnostics
(VPT)
Select Model
Select Model
Rating:50Neutral
Price Target:
C$0.12
▲(0.00% Upside)
Action:ReiteratedDate:12/30/25
The score is held back primarily by weak financial fundamentals (ongoing losses, cash burn, and negative equity). Technicals are moderately constructive with improving momentum, and corporate updates are directionally positive, but valuation support is limited due to negative earnings and no dividend indicated.
Positive Factors
Technological Advancements
These advancements enhance VentriPoint's product offerings, potentially increasing market share and improving competitive positioning in cardiac diagnostics.
Negative Factors
Negative Equity
Negative equity reflects financial instability, which can limit the company's ability to invest in growth and may pose challenges in securing additional financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Technological Advancements
These advancements enhance VentriPoint's product offerings, potentially increasing market share and improving competitive positioning in cardiac diagnostics.
Read all positive factors
VentriPoint Diagnostics (VPT) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$18.77M
Dividend YieldN/A
Average Volume (3M)106.78K
Price to Earnings (P/E)―
Beta (1Y)-0.25
Revenue Growth28.59%
EPS Growth23.46%
CountryCA
Employees10
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding187,659,200
10 Day Avg. Volume85,718
30 Day Avg. Volume106,775
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)-5.31
Price to Sales (P/S)166.31
P/FCF Ratio-4.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
VentriPoint Diagnostics Business Overview & Revenue Model
Company Description
Ventripoint Diagnostics Ltd., a medical device company, develops and commercializes diagnostic tools that monitor patients with heart disease worldwide. The company offers Ventripoint Medical System (VMS), a medical imaging system that is used to ...
How the Company Makes Money
VentriPoint Diagnostics generates revenue primarily through the sale and licensing of its VMS+ imaging system to healthcare facilities, including hospitals and clinics. The company also earns income from providing related services such as training...
VentriPoint Diagnostics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
9
Very Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 175.62K | 95.17K | 49.18K | 68.17K | 0.00 | 36.02K |
| Gross Profit | 144.92K | 95.17K | 42.43K | 57.81K | -48.81K | 26.27K |
| EBITDA | -3.66M | -4.76M | -4.74M | -4.79M | -3.81M | -1.58M |
| Net Income | -4.06M | -4.92M | -4.87M | -4.87M | -3.88M | -1.85M |
Balance Sheet | ||||||
| Total Assets | 377.12K | 658.02K | 1.88M | 5.98M | 9.54M | 801.57K |
| Cash, Cash Equivalents and Short-Term Investments | 68.32K | 60.55K | 1.29M | 5.19M | 9.27M | 526.03K |
| Total Debt | 2.35M | 1.63M | 412.44K | 459.08K | 159.97K | 1.37M |
| Total Liabilities | 5.03M | 3.64M | 1.69M | 1.42M | 1.21M | 3.15M |
| Stockholders Equity | -4.66M | -2.98M | 189.71K | 4.55M | 8.33M | -2.35M |
Cash Flow | ||||||
| Free Cash Flow | -1.68M | -3.39M | -3.80M | -4.14M | -3.15M | -1.10M |
| Operating Cash Flow | -1.68M | -3.39M | -3.80M | -4.14M | -3.15M | -1.10M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | -4.26K | -3.76K |
| Financing Cash Flow | 1.65M | 2.20M | -102.36K | 87.65K | 11.89M | 1.62M |
VentriPoint Diagnostics Technical Analysis
Negative
0.12
Price Trends
0.12
Negative
0.11
Negative
0.11
Negative
Market Momentum
>-0.01
Positive
36.12
Neutral
22.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:VPT, the sentiment is Negative. The current price of 0.12 is above the 20-day moving average (MA) of 0.11, above the 50-day MA of 0.12, and above the 200-day MA of 0.11, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 36.12 is Neutral, neither overbought nor oversold. The STOCH value of 22.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:VPT.
VentriPoint Diagnostics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | C$18.77M | -5.28 | 106.68% | ― | 28.59% | 23.46% | |
46 Neutral | C$329.91M | -5.47 | -85.73% | ― | 72.03% | -1.47% | |
46 Neutral | C$65.55M | -11.76 | -269.41% | ― | 1.46% | 6.91% | |
44 Neutral | C$44.77M | -5.70 | -220.14% | ― | 209.29% | 35.38% |
* Healthcare Sector Average
TSE:VPT
VentriPoint Diagnostics
0.10
-0.04
-25.93%
TSE:IME
Imagin Medical
0.02
0.00
0.00%
TSE:PINK
Perimeter Medical Imaging AI
0.36
-0.05
-11.25%
TSE:PRN
Profound Medical
9.09
2.77
43.83%
TSE:TLT
Theralase Technologies
0.26
0.05
27.50%
VentriPoint Diagnostics Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Ventripoint Doubles Private Placement to $1 Million on Strong Investor Demand
Positive
Jan 7, 2026
Ventripoint Diagnostics Ltd. has doubled the size of its previously announced non-brokered private placement from $500,000 to $1,000,000 after strong investor demand, subject to TSX Venture Exchange approval. The financing consists of units made u...
Business Operations and StrategyPrivate Placements and Financing
Ventripoint Launches $500,000 Non-Brokered Private Placement to Support Growth
Positive
Dec 30, 2025
Ventripoint Diagnostics Ltd. has launched a non-brokered private placement of up to 5,000,000 units at $0.10 per unit to raise as much as $500,000, subject to TSX Venture Exchange approval. Each unit consists of one common share and one warrant ex...
Business Operations and Strategy
Ventripoint Hires Summit Sciences to Build ROI Models for AI Cardiac Imaging Platform
Positive
Dec 18, 2025
Ventripoint Diagnostics has engaged consulting firm Summit Sciences and its CEO Dana Friesen to develop advanced, customer-focused financial and return-on-investment models that quantify the economic benefits of adopting the company’s AI-dri...
Business Operations and StrategyPrivate Placements and Financing
Ventripoint Diagnostics to Issue Shares for Debenture Interest Payments
Positive
Dec 18, 2025
Ventripoint Diagnostics Ltd. announced its plan to issue 1,145,627 common shares to satisfy $103,106.29 in debenture interest payments, subject to TSXV approval. This initiative demonstrates the company’s strategic approach to manage its fin...
Business Operations and Strategy
Ventripoint and Nisg̱a’a Valley Health Authority Partner for Global AI-Enhanced Heart Care
Positive
Dec 12, 2025
Ventripoint Diagnostics has announced a partnership with the Nisg̱a’a Valley Health Authority to develop a global model for delivering advanced cardiac imaging to remote and Indigenous communities. This new hub-and-spoke model aims to p...
Business Operations and StrategyExecutive/Board Changes
Ventripoint Diagnostics Appoints New CFO to Drive Global Expansion
Positive
Dec 3, 2025
Ventripoint Diagnostics has appointed David Swetlow as Chief Financial Officer, marking a significant step in strengthening its leadership team as the company enters a new growth phase. Swetlow’s extensive experience in financial and public ...
Business Operations and StrategyPrivate Placements and Financing
Ventripoint Diagnostics Settles Debt with Share Issuance
Positive
Nov 6, 2025
Ventripoint Diagnostics Ltd. has announced a debt settlement agreement, converting $542,591.50 of debt into 5,425,915 common shares at $0.10 per share, subject to a hold period and TSX Venture Exchange approval. This move aims to conserve cash for...
Business Operations and StrategyProduct-Related Announcements
Ventripoint Collaborates with PHC Ventures to Enhance Cardiac Imaging Access
Positive
Oct 29, 2025
Ventripoint Diagnostics has announced a collaboration with Providence Health Care Ventures to validate its AI-enabled VMS+™ platform at St. Paul’s Hospital in Vancouver. This partnership aims to demonstrate how the platform can reduce ...
Business Operations and StrategyProduct-Related Announcements
Ventripoint Diagnostics Advances Commercialization of VMS+™ System
Positive
Oct 24, 2025
Ventripoint Diagnostics Ltd. has announced advancements in its business plan, focusing on the commercialization of its VMS+™ system by transitioning its user base from research to routine clinical adoption. The company is expanding its comme...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.